Novo Nordisk Secures Rights to Lexicon’s LX9851, Aiming to Enhance Obesity Treatments

Novo Nordisk has acquired global rights to Lexicon Pharmaceuticals’ LX9851, an oral small molecule drug designed to promote weight loss through a first-in-class mechanism. The licensing agreement follows promising preclinical data from studies that combined LX9851 with semaglutide, the active ingredient in Novo Nordisk’s obesity medication Wegovy.

Lexicon Pharmaceuticals previously reported encouraging results from tests of LX9851 when used alongside semaglutide. These findings suggest potential for the combination therapy in addressing obesity. The agreement grants Novo Nordisk exclusive worldwide rights to further develop and commercialize LX9851, which could complement its existing portfolio of GLP-1 receptor agonists. Details regarding financial terms or timelines for clinical development were not disclosed.

Date: March, 2025

Newsflash | Powered by GeneOnline AI

Related posts:

Novo Nordisk Introduces Lower-Cost Wegovy via Direct-to-Patient Sales Platform Novo Nordisk Announces Price Reduction for Wegovy Weight Loss Drug Amid Growing Demand Novo Nordisk Rejoins British Pharmaceutical Industry Association After Suspension What the PlayStation Network Outage Can Teach the Biotech Industry

Author

Mark Chiang

紐約 NYU Computer Science 碩士 紐澤西 UMDNJ Biomedical Informatics 博士 中研院博士後 台灣大學博士後